DD292135A5 - Verfahren zur herstellung einer stabilen zusammensetzung von cisplatin fuer die parenterale verabreichung - Google Patents
Verfahren zur herstellung einer stabilen zusammensetzung von cisplatin fuer die parenterale verabreichung Download PDFInfo
- Publication number
- DD292135A5 DD292135A5 DD89334564A DD33456489A DD292135A5 DD 292135 A5 DD292135 A5 DD 292135A5 DD 89334564 A DD89334564 A DD 89334564A DD 33456489 A DD33456489 A DD 33456489A DD 292135 A5 DD292135 A5 DD 292135A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- cisplatin
- solution
- composition according
- sodium chloride
- chloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000007911 parenteral administration Methods 0.000 title claims abstract 4
- 238000004519 manufacturing process Methods 0.000 title description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 124
- 229960004316 cisplatin Drugs 0.000 claims abstract description 124
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 128
- 239000000243 solution Substances 0.000 claims description 89
- 239000011780 sodium chloride Substances 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 13
- 229910052697 platinum Inorganic materials 0.000 abstract description 6
- 241000894007 species Species 0.000 description 18
- 238000009472 formulation Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- PKPZZAVJXDZHDW-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;hydrochloride Chemical compound Cl.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PKPZZAVJXDZHDW-LJTMIZJLSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 208000034404 cisplatin toxicity Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- CEALXSHFPPCRNM-UHFFFAOYSA-L disodium;carboxylato carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OC([O-])=O CEALXSHFPPCRNM-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000076 hypertonic saline solution Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012087 reference standard solution Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27033088A | 1988-11-14 | 1988-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD292135A5 true DD292135A5 (de) | 1991-07-25 |
Family
ID=23030884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD89334564A DD292135A5 (de) | 1988-11-14 | 1989-11-14 | Verfahren zur herstellung einer stabilen zusammensetzung von cisplatin fuer die parenterale verabreichung |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0369714A1 (da) |
| JP (1) | JPH0321252A (da) |
| AU (1) | AU613810B2 (da) |
| DD (1) | DD292135A5 (da) |
| DK (1) | DK567689A (da) |
| FI (1) | FI895340A7 (da) |
| HU (1) | HU208074B (da) |
| IL (1) | IL92292A0 (da) |
| NO (1) | NO894505L (da) |
| NZ (1) | NZ231363A (da) |
| OA (1) | OA10033A (da) |
| PT (1) | PT92300A (da) |
| YU (1) | YU216689A (da) |
| ZA (1) | ZA898652B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1165455B (it) * | 1983-07-06 | 1987-04-22 | Consiglio Nazionale Ricerche | Composizioni polimeriche a base di policaprolattame |
| JP2006342058A (ja) * | 2003-06-20 | 2006-12-21 | Otsuka Pharmaceut Factory Inc | プラスチック製容器入りシスプラチン製剤 |
| DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| KR20240041285A (ko) * | 2021-06-01 | 2024-03-29 | 프리보 테크놀로지스, 인코포레이티드 | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445172B (sv) * | 1978-05-30 | 1986-06-09 | Bristol Myers Co | Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| AU541056B2 (en) * | 1980-03-31 | 1984-12-13 | Bristol-Myers Company | Pharmaceuticals formulations |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| JPH072645B2 (ja) * | 1986-06-12 | 1995-01-18 | 日本化薬株式会社 | 新規白金錯体製剤 |
-
1989
- 1989-11-09 FI FI895340A patent/FI895340A7/fi not_active Application Discontinuation
- 1989-11-10 NZ NZ231363A patent/NZ231363A/en unknown
- 1989-11-13 EP EP89311732A patent/EP0369714A1/en not_active Ceased
- 1989-11-13 NO NO89894505A patent/NO894505L/no unknown
- 1989-11-13 DK DK567689A patent/DK567689A/da not_active Application Discontinuation
- 1989-11-13 OA OA59680A patent/OA10033A/fr unknown
- 1989-11-13 PT PT92300A patent/PT92300A/pt not_active Application Discontinuation
- 1989-11-13 IL IL92292A patent/IL92292A0/xx not_active IP Right Cessation
- 1989-11-13 ZA ZA898652A patent/ZA898652B/xx unknown
- 1989-11-13 JP JP1294763A patent/JPH0321252A/ja active Pending
- 1989-11-14 AU AU44683/89A patent/AU613810B2/en not_active Ceased
- 1989-11-14 HU HU895890A patent/HU208074B/hu not_active IP Right Cessation
- 1989-11-14 DD DD89334564A patent/DD292135A5/de not_active IP Right Cessation
- 1989-11-14 YU YU02166/89A patent/YU216689A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4468389A (en) | 1990-05-17 |
| FI895340A7 (fi) | 1990-05-15 |
| IL92292A0 (en) | 1990-07-26 |
| YU216689A (en) | 1991-06-30 |
| AU613810B2 (en) | 1991-08-08 |
| ZA898652B (en) | 1990-07-25 |
| EP0369714A1 (en) | 1990-05-23 |
| FI895340A0 (fi) | 1989-11-09 |
| NZ231363A (en) | 1992-03-26 |
| HUT52373A (en) | 1990-07-28 |
| NO894505D0 (no) | 1989-11-13 |
| DK567689A (da) | 1990-05-15 |
| DK567689D0 (da) | 1989-11-13 |
| OA10033A (en) | 1996-10-14 |
| HU208074B (en) | 1993-08-30 |
| HU895890D0 (en) | 1990-02-28 |
| PT92300A (pt) | 1990-05-31 |
| NO894505L (no) | 1990-05-15 |
| JPH0321252A (ja) | 1991-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3536896C2 (de) | Lyophilisiertes, ein Anthracyclinglycosid enthaltendes pharmazeutisches Präparat und Verfahren zur Herstellung einer sterilen injizierbaren Lösung hieraus | |
| DE4344824C1 (de) | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung | |
| DE602005001833T2 (de) | Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide | |
| DE69708121T3 (de) | Halogenid-enthaltende insulinzubereitungen | |
| DE69530412T2 (de) | Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) | |
| DE69621942T2 (de) | Verbessertes herstellungsverfahren und zusammensetzung für therapeutisches cisplatin (cddp) | |
| EP0684839B1 (de) | Verfahren zur herstellung kolloidaler wässriger lösungen schwer löslicher wirkstoffe | |
| DE69230672T2 (de) | Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält | |
| DE3333024A1 (de) | Neue pharmakologische zusammensetzungen auf basis von cis-platin und verfahren zu deren herstellung | |
| DE69229318T2 (de) | Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe | |
| DE69625200T2 (de) | Arzneimittel enthaltend lamotrigin | |
| WO2001078732A1 (de) | Lagerstabile infusionslösung des ciprofloxacins | |
| EP1466600B1 (de) | Gebrauchsfertige Oxaliplatin-Lösungen | |
| DD292135A5 (de) | Verfahren zur herstellung einer stabilen zusammensetzung von cisplatin fuer die parenterale verabreichung | |
| DE69016087T2 (de) | Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung. | |
| DD244292A5 (de) | Trockensubstanzen und stabile suspensionen | |
| DE69500490T2 (de) | Glattmuskelrelaxierende Arzneizubereitungen | |
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE60001489T2 (de) | Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid | |
| AT401469B (de) | Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung | |
| DE69709404T2 (de) | Minderung der toxischen effekte des carboplatins durch verwendung von dithioethern | |
| DE69115102T2 (de) | Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren. | |
| DE69427595T2 (de) | Antitumormittel auf basis von carboplatin und herstellung desselben | |
| DE69619518T2 (de) | Wasserlösliche pulverzusammensetzungen und ihre verwendungen | |
| DE69231098T2 (de) | Lyophilisierte zusammensetzung, die s(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis(2,6-piperazindion)enthält |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |